Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F M Gotch

Showing results (11-20 of 64) with videos related to

Pageof 7
Sort By:
British Journal of Cancer|August 1, 1978
Analysis of synergy between cyclophosphamide therapy and immunity against a mouse tumourD M Chassoux, F M Gotch, I C MacLennan
Nature|February 16, 1989
Class I cross-restricted T cells reveal low responder allele due to processing of viral antigenH C Bodmer, F M Gotch, A J McMichael
AIDS (London, England)|January 1, 1997
New observations on cellular immune responses to HIV and T-cell epitopesF M Gotch, R A Koup, J T Safrit
Molecular Biology & Medicine|September 1, 1983
Plasma membranes from influenza virus-infected cells induce in vitro human secondary virus-specific cytotoxic T lymphocyte responsesJ E Hildreth, F M Gotch, A J McMichael
Immunology|February 1, 1974
Effector activating determinants on IgG. II. Differentiation of the combining sites for C1q from those for cytotoxic K cells and neutrophils by plasmin digestion of rabbits IgGI C MacLennan, G E Connell, F M Gotch
European Journal of Immunology|December 1, 1982
Lysis of allogeneic human lymphocytes by nonspecifically activated T-like cellsA J McMichael, F M Gotch, J E Hildreth
Clinical and Experimental Immunology|September 5, 2001
T-cell re-population in HIV-infected children on highly active anti-retroviral therapy (HAART)D J King, F M Gotch, E L Larsson-Sciard, et al.
Immunology|September 1, 1973
Effector activating determinants on IgG. I. The distribution and factors influencing the display of complement, neutrophil and cytotoxic B-cell determinants on human IgG sub-classesI C MacLennan, A Howard, F M Gotch, et al.
AIDS (London, England)|July 8, 2000
New insights and approaches regarding B- and T-cell epitopes in HIV vaccine designJ Oscherwitz, F M Gotch, K B Cease, et al.
AIDS Research and Human Retroviruses|December 2, 1999
Assessment of type 1 and type 2 cytokines in HIV type 1-infected individuals: impact of highly active antiretroviral therapyN Imami, C Antonopoulos, G A Hardy, et al.
Pageof 7

Showing results (11-20 of 64) with videos related to

Sort By:
Pageof 7
British Journal of Cancer|August 1, 1978
Analysis of synergy between cyclophosphamide therapy and immunity against a mouse tumourD M Chassoux, F M Gotch, I C MacLennan
Nature|February 16, 1989
Class I cross-restricted T cells reveal low responder allele due to processing of viral antigenH C Bodmer, F M Gotch, A J McMichael
AIDS (London, England)|January 1, 1997
New observations on cellular immune responses to HIV and T-cell epitopesF M Gotch, R A Koup, J T Safrit
Molecular Biology & Medicine|September 1, 1983
Plasma membranes from influenza virus-infected cells induce in vitro human secondary virus-specific cytotoxic T lymphocyte responsesJ E Hildreth, F M Gotch, A J McMichael
Immunology|February 1, 1974
Effector activating determinants on IgG. II. Differentiation of the combining sites for C1q from those for cytotoxic K cells and neutrophils by plasmin digestion of rabbits IgGI C MacLennan, G E Connell, F M Gotch
European Journal of Immunology|December 1, 1982
Lysis of allogeneic human lymphocytes by nonspecifically activated T-like cellsA J McMichael, F M Gotch, J E Hildreth
Clinical and Experimental Immunology|September 5, 2001
T-cell re-population in HIV-infected children on highly active anti-retroviral therapy (HAART)D J King, F M Gotch, E L Larsson-Sciard, et al.
Immunology|September 1, 1973
Effector activating determinants on IgG. I. The distribution and factors influencing the display of complement, neutrophil and cytotoxic B-cell determinants on human IgG sub-classesI C MacLennan, A Howard, F M Gotch, et al.
AIDS (London, England)|July 8, 2000
New insights and approaches regarding B- and T-cell epitopes in HIV vaccine designJ Oscherwitz, F M Gotch, K B Cease, et al.
AIDS Research and Human Retroviruses|December 2, 1999
Assessment of type 1 and type 2 cytokines in HIV type 1-infected individuals: impact of highly active antiretroviral therapyN Imami, C Antonopoulos, G A Hardy, et al.
Pageof 7